Special Issue

Advanced Ocular Drug Delivery

Guest Editors:

Prof. Dr. Tao L. Lowe
Pharmaceutical Sciences & Biomedical Engineering,
University of Tennessee Health Science Center, Memphis, TN 38163, USA
tlowe4@uthsc.edu

Dr. Dileep Reddy Janagam
Plough Center for Sterile Drug Delivery, University of Tennessee Health Science Center, Memphis, TN 38163, USA
djanagam@uthsc.edu

Deadline for manuscript submissions: 31 July 2017

Message from the Guest Editors

Because of the presence of various static, dynamic and metabolic ocular barriers, the delivery of drugs to the targeted sites of action in the eye is often very challenging and requires interdisciplinary approaches involving basic, applied and clinical sciences. In recent years, increasing progress has been made to develop novel and safe materials, devices and methods to overcome ocular barriers to deliver therapeutic agents to targeted sites in the eye. This Special Issue invites original technical papers and reviews to discuss the broad scope of recent developments, future directions, possible challenges, and regulatory and ethical issues in advancing ocular drug delivery for clinical and commercial translation. The focus is on, but not limited to biomaterials; nanotechnology; personalized ophthalmology; theranostics; ocular disease targets; biomarkers; ocular transport; ocular pharmacokinetics; industrial development; regulatory and ethical considerations; clinical studies; intellectual property; and commercialization.

Author Benefits

Open Access: free for readers, with publishing fees paid by authors or their institutions.

High visibility: citations available in PubMed, full-text archived in PubMed Central. Covered by Scopus: papers published between 2013 and 2015 have been cited 3.73 times, on average, in 2016 (CiteScore 2016).

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 31 days after submission; acceptance to publication is undertaken in 8 days (median values for papers published in this journal in 2016).